Background:
Post-stroke cognitive impairment
(PSCI) represents a serious post-stroke complication with poor cognitive
consequences. A vascular consequence after a stroke is that the occurrence and
progression of PSCI may be closely related to blood pressure (BP). Thus, we
systematically reviewed and performed a meta-analysis of the literature to
examine the correlations between BP and PSCI.
Methods:
We systematically
queried databases, including PubMed, the Cochrane Library, Embase, and Scopus,
and conducted meta-analyses on studies reporting odds ratios (ORs) related to the
association between BP and PSCI. Two authors autonomously assessed all titles,
abstracts, and full texts and extracted data following the Meta-Analysis of
Observational Studies in Epidemiology guidelines. The quality of the studies was
evaluated using the modified Newcastle–Ottawa scale.
Results:
Meta-analyses incorporated 12 articles comprising a cumulative participant cohort
of 21,732 individuals. The quality assessment indicated good in five studies,
fair in one study, and poor in six. Through meta-analyses, we found that
hypertension, systolic or diastolic BP (SBP or DBP) was significantly associated
with PSCI (OR 1.53, 95% confidence interval (CI), 1.18–1.99;
p
= 0.001,
= 66%; OR 1.13, 95% CI, 1.05–1.23;
p
= 0.002,
= 52%; OR 1.38, 95% CI, 1.11–1.72;
p
= 0.004,
= 90%, respectively). In the subgroup
analysis, SBP
120 mmHg, 120–139 mmHg, 140–159 mmHg, 160–179 mmHg,
and DBP
100 mmHg highly predicted the occurrence of PSCI (OR 1.15,
p
= 0.0003; OR 1.26,
p
= 0.010; OR 1.15,
p
= 0.05; OR
1.02,
p
= 0.009; OR 1.96,
p
0.00001, respectively).
However, the predictive effect of BP for PSCI declines when SBP
180 mmHg
and DBP
99 mmHg (
p
0.05). Statistical heterogeneity was
moderate to high, and publication bias was detected in SBP for PSCI.
Conclusions:
Considering the multifactorial etiology of PSCI, it is
difficult to conclude that BP is an independent risk factor for PSCI. Given the
restricted inclusion of studies, caution is advised when interpreting the
findings from this meta-analysis. Subsequent investigations with substantial
sample sizes are essential to exploring BP as a prospective target for addressing
PSCI.
Trial Registration Number:
CRD42023437783 from PROSPERO.